市场调查报告书
商品编码
1394978
卡培他滨市场规模 - 按适应症(乳腺、结直肠、胃、胰腺)、合成类型(基于化学的 API、生物 API、高效 API、模式)、2023-2032 年全球预测Capecitabine Market Size - By Indication (Breast, Colorectal, Gastric, Pancreatic), By Synthesis Type (Chemical Based API, Biological API, Highly Potent API, Mode), Global Forecast 2023- 2032 |
预计从 2023 年到 2032 年,卡培他滨市场规模将以 4.9% 的CAGR扩大。包括乳腺癌和结直肠癌在内的各种癌症发病率的上升正在推动对几种有效化疗药物的需求。
癌症治疗方案的快速进步正在推动卡培他滨作为口服化疗方案的采用。此外,持续的研发活动以及产品批准数量的增加正在提高卡培他滨的功效和安全性。例如,2022 年 12 月,美国 FDA 批准了卡培他滨片剂的更新标籤,作为更新计画的一部分。该倡议由肿瘤学卓越中心领导,旨在确保特定老肿瘤药物的临床意义和科学最新资讯。
全球人口老化的不断加剧,加上癌症意识的增强,凸显了卡培他滨在解决日益增长的癌症负担方面的重要性。口服给药的便利性和减少医院就诊以提高患者依从性是推动市场成长的其他因素。
卡培他滨产业分为适应症、合成类型、模式和地区。
根据迹象,到 2032 年,结直肠癌领域的行业价值预计将以 5.3% 的CAGR增长。结直肠癌患病率的增加和癌症治疗方案的迅速进步正在推动卡培他滨作为化疗方案的疗效。因此,卡培他滨治疗大肠直肠癌的有效性将促进该细分市场的成长。
生物 API 合成类领域的卡培他滨市场份额预计从 2023 年到 2032 年将以 4.9% 的CAGR增长。这种增长归因于生物技术的不断进步、对标靶治疗的需求不断增加以及生物合成活性药物成分的功效。透过生物合成开发卡培他滨将进一步促进其在製药领域的相关性和采用。
从地区来看,受乳癌和大肠癌发生率上升的推动,亚太地区卡培他滨产业预计 2023 年至 2032 年CAGR为 5.7%。医疗基础设施的不断进步、人们对癌症治疗选择的认识不断提高以及人口老化的不断增长将进一步推动该地区卡培他滨的消费。
Capecitabine market size is projected to expand at 4.9% CAGR from 2023 to 2032. The rising incidence of various cancers, including breast and colorectal is fueling the demand for several effective chemotherapy drugs.
The rapid advancements in cancer treatment protocols is driving the adoption of capecitabine as an oral chemotherapy option. Additionally, the ongoing R&D activities along with the rising number of product approvals are leading to improved efficacy and safety of capecitabine. For instance, in December 2022, the U.S. FDA approved the updated labeling for capecitabine tablets as part of Project Renewal. This initiative, led by the Oncology Center of Excellence, aims to ensure clinically meaningful as well as scientifically up-to-date information for specific older oncology drugs.
The growing aging population across the globe coupled with the increasing cancer awareness is underscoring the significance of capecitabine in addressing the growing burden of cancer. The convenience of oral administration and reduced hospital visits for enhanced patient compliance are other factors driving the market growth.
The capecitabine industry is segregated into indication, synthesis type, mode, and region.
Based on indication, the industry value from the colorectal cancer segment is estimated to rise at 5.3% CAGR through 2032. The increasing prevalence of colorectal cancer and the surging advancements in cancer treatment protocols is driving the efficacy of capecitabine as a chemotherapy option. The effectiveness of capecitabine in treating colorectal cancer will, thus, add to the segment growth.
Capecitabine market share from the biological API synthesis type segment is projected to increase at 4.9% CAGR from 2023 to 2032. This growth is ascribed to the growing advancements in biotechnology, the increasing demand for targeted therapies, and the efficacy of biologically synthesized active pharmaceutical ingredients. The development of capecitabine through biological synthesis will further contribute to its relevance and adoption in the pharmaceutical sector.
Regionally, the Asia Pacific capecitabine industry is slated to expand at 5.7% CAGR from 2023 to 2032, driven by the increasing incidence of breast and colorectal cancers. The rising advancements in healthcare infrastructure, increasing awareness of cancer treatment options, and the growing aging population will further drive the consumption of capecitabine across the region.